A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications

[1]  F. Underwood,et al.  The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. , 2022, The lancet. Gastroenterology & hepatology.

[2]  K. Cusi,et al.  American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). , 2022, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  V. Wong,et al.  Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease , 2022, Hepatology.

[4]  K. Cusi,et al.  A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.

[5]  Fei Wang,et al.  Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese:A Prospective Cohort Study , 2022, Frontiers in Endocrinology.

[6]  Our world in data , 2022 .

[7]  N. Lanthier,et al.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.

[8]  D. Thabut,et al.  Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. , 2021, Journal of hepatology.

[9]  J. Machann,et al.  Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes , 2021, Nature Medicine.

[10]  H. D. de Valk,et al.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2020, The Journal of clinical endocrinology and metabolism.

[11]  M. Shimabukuro,et al.  Factors Associated with Risk of Diabetic Complications in Novel Cluster-Based Diabetes Subgroups: A Japanese Retrospective Cohort Study , 2020, Journal of clinical medicine.

[12]  S. Asch,et al.  Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[13]  V. Wong,et al.  Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study , 2020, Hepatology.

[14]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[15]  L. Groop,et al.  Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. , 2019, The lancet. Diabetes & endocrinology.

[16]  K. Cusi,et al.  Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[17]  M. Cnop,et al.  OGTT is recommended for glucose homeostasis assessments in Friedreich ataxia , 2018, Annals of clinical and translational neurology.

[18]  B. Finck.  Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis , 2018, Diabetes.

[19]  M. Ziol,et al.  Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. , 2018, The lancet. Gastroenterology & hepatology.

[20]  Zhongheng Zhang,et al.  Overview of model validation for survival regression model with competing risks using melanoma study data. , 2018, Annals of translational medicine.

[21]  R. Bataller,et al.  Alcoholic liver disease , 2018, Nature Reviews Disease Primers.

[22]  L. Groop,et al.  Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.

[23]  Gianluca Svegliati-Baroni,et al.  Lipotoxicity and the gut-liver axis in NASH pathogenesis. , 2018, Journal of hepatology.

[24]  M. Ziol,et al.  Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[25]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[26]  Vincent Wai-Sun Wong,et al.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study , 2015, Gut.

[27]  Gérard Forzy,et al.  Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C , 2009, Hepatology.

[28]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[29]  A. Brazzale,et al.  Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test , 2005, Diabetologia.

[30]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[31]  J. Levy,et al.  Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program , 1998, Diabetes Care.

[32]  J. Concato,et al.  The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.

[33]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[34]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .